Cresset Asset Management, LLC Nuvation Bio Inc. Transaction History
Cresset Asset Management, LLC
- $17.3 Billion
- Q4 2024
A detailed history of Cresset Asset Management, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Cresset Asset Management, LLC holds 136,435 shares of NUVB stock, worth $255,133. This represents 0.0% of its overall portfolio holdings.
Number of Shares
136,435
Previous 134,290
1.6%
Holding current value
$255,133
Previous $308,000
17.53%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding NUVB
# of Institutions
163Shares Held
151MCall Options Held
1.2KPut Options Held
223K-
Decheng Capital LLC Menlo Park, CA26MShares$48.5 Million14.81% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$30.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.7MShares$29.4 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$24.4 Million53.05% of portfolio
-
Octagon Capital Advisors LP New York, NY9.2MShares$17.2 Million5.46% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $406M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...